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A possible future end-game for cigarettes is explored in the context of the historical progress made to date by tobacco
control. Despite good progress, there remains an urgent need to increase the use of proven tobacco control policies and
practices for prevention and cessation. The problem is worse than previously thought and the 50th anniversary United States
Surgeon General’s report indicates the overwhelming majority of avoidable deaths are caused by combusting of tobacco,
primarily cigarettes. The report highlights for the first time the addition of a harm minimization strategy to enhance proven
tobacco control efforts and thus much more rapidly speed the obsolescence of cigarettes. Harm minimization can be two
pronged. First, it can boost proven tobacco control polices to make cigarettes more expensive and less appealing and
accessible to maximize the fact that cigarettes are orders of magnitude the most harmful of all tobacco delivery systems.
Second, harm minimization can support use of substantially less harmful but appealing alternatives to substitute for lethal
cigarettes for those users who are unable or unwilling to quit smoking. A future end-game might prudently manage
emerging new products like e-cigarettes to help boost the difference in harm between them and lethal cigarettes. Harm
minimization could help to accelerate the end of the century-long dominance of the cigarette in what has been called
“the golden holocaust”. Rather than these emerging delivery devices being used to replace lethal cigarettes in what
might be termed a David versus Goliath strategy to disrupt the status quo, there is also legitimate concern that these
new products could undermine historically successful tobacco control efforts, especially youth prevention, if allowed free
reign. What can the data really tell us about the potential for e-cigarettes to be helpful or harmful? The emerging but
limited scientific evidence and the inherent methodological constraints in study designs, points to the need for caution
in prematurely interpreting results in a manner that could mislead policymakers.Rosen and Peled-Raz [1] provide an illuminating history of
the lifesaving advances in tobacco control in Israel and exam-
ine future directions, including the rise of e-cigarettes. Israel
like the United States (U.S.) is increasingly embracing more
components of the FrameworkConvention for TobaccoCon-
trol [1, 2]. In figure 1, Rosen and Peled-Raz provide an impres-
sive visual display of key policy and practice milestones,
especially those implemented over the last 15 years [1]. In the
U.S., the 2014 publication of the 50th anniversary edition of
the SurgeonGeneral’s Report includes similar policy and prac-
tice reviews, not all of which have been implemented at the* Correspondence: dabrams@legacyforhealth.org
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increases; indoor air restrictions; education campaigns; no
sales to minors; restricting marketing that targets youth;
health insurance coverage for cessation treatment; protecting
the unborn and pregnant moms from smoking; and protect-
ing bystanders from environmental smoke pollution [3].Mak-
ing the next generation of youth tobacco-free and helping
current smokers quit is a top priority of U.S tobacco control,
yet progress will be slow ifmore is not done.
Despite best efforts in Israel to date, the sobering status in
2015 is the still unacceptable statistic of about 8,000 annual
preventable deaths - and Israel is in good company, contrib-
uting its fair share to the about 1 billion deaths projected
globally in the 21st century. The deaths come overwhelm-
ingly from one class of tobacco delivery product: the
century-long behavior of inhaling the toxic smoke emanatingccess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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livered in the form of the mass produced, appealing,
addictive, still NOT overly expensive, and continuously
being engineered for optimal consumer satisfaction, but
nonetheless lethal cigarette. Calls to eliminate ciga-
rettes from the market are increasingly being made [2].
The astute historian Proctor calls the past “cigarette
century” [4] the golden holocaust [5, 6]. In the U.S., ciga-
rettes have prematurely killed over 20 million Ameri-
cans, more lives lost than in all the American wars ever
fought, from the War of Independence to the present.
Proctor repeatedly calls for abolition. He defines a de-
fective product as one that is not simply inherently risky,
but risky by design: intentionally manufactured with an
unacceptable level of risk to optimize the product’s che-
mosensory satisfaction and addiction propensity. Proc-
tor’s plea falls on deaf ears.
As part of an end-game for cigarettes, Warner and
others point out that strong economic disincentives can
have a large impact on preventing youth initiation and
reducing cigarette use, but the tax increases have to be
large and regularly stepped up [7]. Policymakers would
need the political courage to prioritize people’s lives over
commercial profits in line with social justice. Overt
explicit resistance, but more critically inaction and fail-
ure to challenge misguided resistance to prudent policy,
means that vulnerable victims of lethal cigarette access,
especially youth, are not protected from a defective con-
sumer product. A silent majority and a few vocal sup-
porters of a free market actually protect the economic
interests of the Multinational Tobacco companies and
put profits over saving people’s lives. More resources
dedicated to public health and stronger enforcement of
policies that minimize the harms of lethal cigarettes are
sorely needed.
In the U.S. in 2009, in addition to state and federal tax
increases (although still not nearly high enough), a new
“user fee” was also implemented on cigarette sales. The
fees fund the U.S. Food and Drug Administration (FDA)
through a sustained infrastructure (the Center for To-
bacco Products) for tobacco control regulatory oversight.
The fees also fund research and ongoing national surveil-
lance specific to timely and effective regulatory policy-
making. Thus, another doubling of the tax on cigarettes
and imposing a user fee could be powerful tools to prevent
many more precious children alive today from starting to
smoke and encourage smokers to quit.
Rosen and Peled-Raz remind Israel of the formidable
challenges and ask for more resources to make future
opportunities and dreams come true to protect all
Israelis, both Jewish and Arab, both men and women.
As in the U.S., there is a need for more financial re-
sources to further strengthen science-informed policy
and practice [1].The U.S. Surgeon General’s 2014 report [3] also points
out that more must be done in addition to the trad-
itional proven tobacco control measures to hasten the
end- game for tobacco [7]. For those who cannot or do
not want to stop smoking, alternative less harmful prod-
ucts, in addition to approved medications and behavior
therapy, should now be considered and prudently regu-
lated. Specifically, and consistent with Warner’s [7] and
with Rosen and Peled-Raz’ s [1] end-game examination
of future directions, the U.S. Surgeon General suggested
the addition of harm minimization strategies to be added
to proven historical tobacco control strategies:
“Death… is overwhelmingly caused by cigarettes and
other combustibles… promotion of e-cigarettes and
other innovative products is… likely to be beneficial
where the appeal, accessibility and use of cigarettes
are rapidly reduced” (pp. 15–17) [3].
Harm minimization is a two-pronged strategy to
heighten and not diminish the differences between the
massively harmful cigarette and less harmful alterna-
tives. The challenging question raised is: what is the
best way to implement harm minimization in this rap-
idly changing landscape, as a pragmatic set of new tools
to speed the obsolescence of lethal defective cigarettes?
Is this a David versus Goliath strategy to disrupt the
status quo of the powerful tobacco corporations? There
are legitimate concerns about how to manage emerging
products like e-cigarettes. The science is still too pre-
liminary to be able to inform policy and practice with
confidence. For example, we need to know how to
ensure that any new reduced harm products are kept
away from youth and used primarily to eliminate much
more lethal cigarettes, rather than to perpetuate or pro-
mote continued use of cigarettes. Nonetheless, Rosen
and Peled-Raz have set the stage for an exploration of
future scenarios to save more lives [1]. Their explor-
ation of end-games raises the thorny issue of what is
known already and what is being interpreted from the
science about the e-cigarette class of emerging prod-
ucts. The uncertainty and strong emotion in addressing
this class of products must be considered in the context
of the opportunity for policies to prudently manage the
potential risks and benefits of these products without
over or under reacting.
Science, emotion and policy
Four centuries ago Sir Francis Bacon wrote: “human un-
derstanding is no dry light but receives infusions from
the will and affections” [8]. When the stakes are high, as
they are in the currently shifting tobacco control land-
scape, fears of unknown and hypothetical consequences
can fuel strong emotion. Can such fears cloud a rational,
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makers and the public? Is this now characteristic of the
situation regarding the class of emerging products repre-
sented by e-cigarettes that may or may not contain
nicotine (and more broadly other emerging alternative
nicotine delivery systems - ANDS)? Bacon’s remarks re-
main pertinent when, 400 years later, scientists relinquish
their dispassionate stance and make policy recommenda-
tions with strong conviction, despite strong disagreement
within their own ranks about making premature conclu-
sions derived from the same and oftentimes sparse data.
This commentary examines whether interpretation of
evidence about ANDS is being clouded by emotion and
past ideology, rather than a reliance on the scientific
method and a rational, humble and cautious approach
based on only preliminary evidence. ANDS represents a
new class of products that is rapidly gaining in popular-
ity and technical innovation. Knowledge regarding their
use, safety and public health significance is accumulat-
ing, but has divided the tobacco control community.
Some are legitimately nervous about ANDS' potentially
deleterious impact on tobacco use behavior and others
view ANDS as an alternative with potential to displace
lethal cigarettes [9]. There are few facts available to pol-
icymakers to guide regulatory decisions at this early
stage. But there are troubling trends in the interpretation
of scant evidence and policy recommendations. Positions
have been taken across the spectrum of the debate about
whether ANDS can be helpful or harmful to public
health. The discomfort is essentially one between an
ideological framework that derives from the past 40 years
of proven tobacco control strategies to eliminate all to-
bacco and nicotine use and those who wish to embrace
the addition of a harm minimization approach to the
traditional status quo framework.
Two brief examples based primarily on the current
situation in America illustrate the nature of the ideo-
logical conflict; one is drawn from data on patterns of
youth uptake and the other from data on adult cessation.
In its general form, the debate can be framed as the chal-
lenge of constructing a new transformational science-based
framework to exploit what could be one of the greatest op-
portunities of the 21st century: To speed the end-game goal
of eliminating tobacco-related deaths caused overwhelm-
ingly by the inhalation of combustible tobacco products
(primarily cigarettes and also cigars, hookah/waterpipe and
related products). ANDS advocates believe that the prod-
ucts can literally speed the demise of combustible tobacco.
Opponents claim these products are yet another wolf in
sheep’s clothing, a Trojan horse that will help to attract
and addict a new generation who will progress in droves to
become lethal lifetime cigarette users. ANDS will also pro-
mote dual use and thus will maintain lethal cigarette use
among current smokers and slow cessation.It is premature to predict how the future will play out,
but a key question is what is it that scientists, advocates,
regulators and policymakers will actually do that helps
or (unwittingly) hinders the speedy demise of the lethal
cigarette [9]. Does ANDS represent a disruptive techno-
logical advance (a sheep in wolf ’s clothing, rather than
the wolf in sheep’s clothing so to speak - a gift horse and
not a Trojan horse, perhaps) that will finally disrupt the
deadly hold that cigarettes have had over a significant
proportion of the world’s population for over a century and
themselves spawned by the invention of the cigarette roll-
ing machine [10, 11]? The first rolling machines invented
in the 1880’s produced about 200 cigarettes per minute,
the modern version produces 18,750 cigarettes per minute
and can run 24 h a day, 7 days per week.
Our view is that ANDS represent a new set of tools
with the potential to minimize harm related to combust-
ible tobacco use [11] but only if they are prudently
managed and marketed to adult smokers and only if the
public is accurately and truthfully informed about them
and how best to use them to eliminate combustible
cigarette use. It must be stressed, however, that traditional
tobacco control strategies and tactics to make lethal ciga-
rettes less appealing, accessible and more expensive should
continue in full – and perhaps, greater force to deter
progression from ANDS to lethal combustibles. Nothing in
this commentary should be interpreted as undermining
current tobacco control efforts [2]. We propose that,
because of the rapidly changing landscape, it is time to add
a prudent and pragmatic harm minimization transforma-
tive framework to the traditional tobacco control views
and interpretations of evidence used to guide practice and
policy.
Uptake and progression or cessation from lethal
cigarettes?
Uptake and progression
An increasing number of studies are being published
based on similar observational designs from surveillance
samples in the U.S., largely cross sectional but some lon-
gitudinal. The studies generally were not designed to
look at the question of whether ANDS deters or pro-
motes the use of lethal cigarettes. Many have included
just one or two questions about ANDS use - typically
lifetime (ever) use and past 30-day (experimental use but
often called current use). ANDS critics claim the studies
replicate one another and they conclude that their
evidence shows that ANDS are dangerous, are likely a
pathway into more lethal cigarette use and are under-
mining the progress made in tobacco control.
One of the most prominent of these studies illustrates
common concerns about the conclusions drawn from
many similar studies [12]. Using data from a large repre-
sentative cross-sectional study of U.S. school students,
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was associated with more use of lethal cigarettes [12].
Strong conclusions and policy recommendations were
drawn, despite the correlational, rather than causal, na-
ture of the study design which they did acknowledge but
none the less stated: “Use of e-cigarettes does not dis-
courage and may encourage, conventional cigarette use
among U.S. adolescents” and “e-cigarette use is aggravat-
ing rather than ameliorating the tobacco epidemic
among youths.” The data do not support the conclusions
[13]. The survey data and design do not in any way
document movement from e-cigarettes to combustible
cigarettes. It’s equally plausible that use of combustible
cigarettes leads to use of e-cigarettes, because they are
perceived as a less harmful alternative for smokers who
are not able or willing to go without smoking or are sim-
ply experimenting with a new and novel product out of
curiosity. Finally, the Dutra and Glantz [12] noted a cor-
relation of use of e-cigarettes with more time spent
using tobacco products, which they believe “… call[s]
into question claims that e-cigarettes are effective as
smoking cessation aids.” But users of e-cigarettes also
had higher intention to quit. This connection may indi-
cate that e-cigarette users may have adopted e-cigarettes
for harm reduction (i.e., to assist with quitting). In any
case, the article cannot examine directionality.
Despite the commonly known and basic limitation of
not inferring direction of causality from observational
data collected at a single time point, the overwhelming
majority of statements and policy recommendations
(based not only on this study but also on several others
of similar design) suggest that ANDS are a pathway into
lethal cigarettes and undermine efforts to quit smoking.
Together the emerging and similar studies appear to
replicate one another and thus seem on the surface to
strengthen what amounts to the same premature and
possibly misleading conclusions. The findings of a
correlation between use of ANDS and cigarettes may ap-
pear to be consistent, but none of the studies can prove
a causal effect, much less confirm its direction; the cor-
relation could also be indicative of underlying shared
vulnerabilities that predispose experimenters to engage
in a variety of risky behaviors, without one being a gate-
way to the others [13].
The context in which the study results were observed
is also telling. According to data from the U.S. National
Youth Tobacco Survey (NYTS), use of lethal cigarettes
actually declined every year from 2011 to 2014 [14].
Therefore, if youth uptake of e-cigarettes were to repre-
sent a threat to public health, this downward trend
would be slowed or reversed as a direct result of ANDS
use. ANDS would have to be causally linked to either
undermining cessation of lethal cigarettes and/or to en-
ticing sufficiently large numbers of youth to progress tolethal cigarette use. To slow or reverse the downward
trend in combustible use the net number of youth who
otherwise would never have smoked cigarettes at all
would have to increase, not simply just the youths who
may now start with ANDS but who later would have
been cigarette smokers anyway. In fact, while these trends
ideally should be tracked up until about age 25 in a longi-
tudinal cohort, the most recent cross-sectional NYTS
2014 data indicates e-cigarette experimental use increased
from 2010 to 2014 from 1.5 % to 2.8 % to 4.5 % to 13.4 %.
But over the same time period use of lethal cigarettes de-
creased steadily by about 10 % per year from 2011 to 2013
(15.8 % to 14.0 % to 12.7 %) and decreased even more rap-
idly to a record low of 9.2 % (a near 25 % reduction from
2013 to 2014) [14, 15].
It is too early to draw any conclusions and longitudinal
data are needed over at least 5 or more years to test the
reality of fears of uptake of ANDS directly leading to
more uptake and progression to lethal cigarette daily
than if they did not exist - and that excess progression
would ultimately undermine public health. It is troubling
that the strong negative conclusions and recommenda-
tions already made may already be clouding what the data
really tell us. As Niaura et al. stated: “Cross-sectional sur-
veys provide us with valuable descriptive information that
prompt us to watch carefully how many youth are using
tobacco products and e-cigarettes, but do not provide
explanations for use” [13]. Prematurely over-interpreting
or misinterpreting data, perhaps based on past ideology,
excessive fear in a changing marketplace or human bias,
does not help the cause of tobacco control or public
health. Implying causal explanations in the absence of ap-
propriate data can lead the health care community and
policymakers down false paths on the road to relieving the
horrific toll that lethal cigarettes impose on society.
Cessation
Key issues regarding ANDS and public health impact
also relate to their potential role in facilitating smoking
cessation: whether they: (a) significantly minimize harm
by substituting for lethal cigarettes; (b) have little effect
on harm because smokers use both products without ap-
preciable reduction in toxicant exposure; or (c) speed up
or delay cessation in those who would otherwise have
quit smoking altogether. In addition, even if ANDS are
substantially lower in harm and can save lives, it must
also be stressed that they are not harmless. Those ANDS
products that contain nicotine and other additives and
flavors do pose some risk and the risk is greater if they
have poor quality control standards, are sold to minors or
marketed in ways that appeal to youth and if the bottles of
the liquid juice are sold without child resistant containers,
accurate labels and clear warnings and instructions for
safe handling. Thus the ideal for minimizing harms (to
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of any tobacco or nicotine product at all.
Like the interpretations of the ANDS uptake data,
some researchers and policymakers and an increasing
number of similarly flawed research study designs and
limited measures have also made strong statements that
ANDS do not aid in cessation, are negatively associated
with cessation and may undermine cessation efforts that
could have been better accomplished by use of FDA-
approved pharmacotherapies such as medical nicotine
replacement – NRTs [16]. The evidence to date does not
support this simple negative interpretation of their data.
Several observational studies, for example, reported that
any use of e-cigarettes is correlated with reduced cessa-
tion [17–19]. In some studies, smokers were not even
asked whether they used e-cigarettes to help them quit
or for how long they tried to use ANDS to quit, but simply
were asked questions like: Did you ever use e-cigarettes in
your lifetime? Without basic information about reasons
for use and duration of use, these negative correlations are
impossible to interpret with respect to helping or hinder-
ing lethal smoking cessation [20]. Other factors, especially
selection bias, may also be at play [20]. For example,
smokers who are, for whatever reasons, less able to quit,
but are more motivated to try a new product, may be
more likely to experiment with e-cigarettes, but either not
be interested in cessation or may have had such prior diffi-
culty with cessation that they are disproportionately likely
to fail again [20].
Two randomized controlled trials with early and
technologically inefficient e-cigarette models still showed
that ANDS are modestly effective in helping some
smokers to quit or reduce lethal cigarette consumption
[21, 22]. Bullen et al. [21] compared ANDS to nicotine
replacement therapy (NRT) and, using the six month
point prevalence outcome criterion employed in the meta-
analysis for the U.S. Clinical Guidelines [23], reported an
encouraging 21.1 % cessation rate for ANDS and 15.6 %
for NRT (not a statistically significant difference), indicat-
ing ANDS are at least as effective as NRTs. A U.S. longitu-
dinal observational study found after 2–3 years, intensive
e-cigarette users (used daily for at least a month for pur-
poses of quitting) had the highest rate of smoking cessa-
tion (20.4 %), compared to intermittent users (more than
once or twice but not daily for a month or more; 8.5 %)
and non-users (12.4 %) [24]. Smokers who used ANDS for
at least a month were six times more likely to be abstinent
2 years later [24]. Another large cross-sectional survey in
the United Kingdom (U.K.) found ANDS users were more
likely to report abstinence than either those who used
NRT or no aid [24]. In the U.K., ANDS use for cessation
has also surpassed use of NRT’s making ANDS potential
for larger scale population impact quite promising.
ANDS may be more appealing, convenient and lessexpensive to millions more smokers than conventional
smoking cessation aids.
More research – especially high quality randomized
controlled trials is needed to further determine whether
and how ANDS can be an effective cigarette cessation or
harm minimization tool [25, 26]. ANDS have also been
shown to reliably decrease adverse symptoms related to
tobacco abstinence (e.g., cravings and urges to smoke,
irritability) [27–31]. The U.K approach to lightly regulate
ANDS and encourage their use for lethal cigarette cessa-
tion is an interesting policy to be watched in the coming
years. However without convincing data some countries
(e.g., Brazil) have outright banned ANDS products while
others have permitted products to be sold without nico-
tine (e.g., Canada, Australia). The different experiences will
accelerate global learning about very different policies
based on sparse data.
Research challenges
Once again, what the data really tell us about ANDS and
cessation of lethal cigarettes stands in sharp contrast to
the strongly stated convictions from a few scientists: that
ANDS impede smoking cessation and can harm tobacco
control efforts. As Bacon’s 400-year old observation re-
minds us, science calls for more rigor and less emotion.
Keeping an open mind to new innovation is important
despite legitimate anxieties. The scientific method calls
for acknowledging equally and skeptically the actual data
for and against ANDS supporting uptake and progres-
sion to lethal cigarettes and in evaluating ANDS’ efficacy
for lethal cigarette cessation [20, 26, 32, 33]. Net public
health impact of ANDS is a complex interaction of many
factors at multiple levels of influence [9]. Systems think-
ing and simulation modeling tools [34] will be needed
along with more informative data before we will be able
to say how best to maximize the benefits of ANDS as a
disruptive technology [35] and minimize the hypothet-
ical harms of ANDS to the population as a whole, users
and non users, especially youth [2, 10, 11, 26, 36].
Conclusion
If properly regulated and responsibly made and mar-
keted, especially by independent manufacturers who
have less conflict as Big tobacco does by also selling le-
thal cigarettes, ANDS have the potential to improve the
public health. Together with traditional tobacco control
strategies ANDS can speed the demise of the lethal
cigarette by deterring progression to lethal cigarettes
among non-users and by providing smokers who do not
want to, or have tried and cannot “just quit”, with a sub-
stantially safer alternative - without causing the suffering
from the devastating health consequences imposed on
them by the need to inhale toxic cigarette smoke. As Dr.
Russell stated so prophetically 40 years ago and which is
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from the tars” [37]. ANDS raise legitimate fears of pos-
sible risks and these need to be watched and managed,
but misinterpreting or selectively presenting negative
preliminary data does not serve the public health. The
precautionary principle is potentially violated if ANDS
are prematurely demonized and are then seen by the
public as simply another dangerous tobacco product in-
stead of a way to make lethal cigarettes obsolete. Then
we may well have missed the tobacco control opportun-
ity of the century [35].
Commentary on
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